• 1. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 2. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
• 3. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 4. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 5. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200

Recent Advances in the Study of Methyl 3-nitro-4-(propylamino)benzoate (CAS: 128429-03-8)

Methyl 3-nitro-4-(propylamino)benzoate (CAS: 128429-03-8) is a chemical compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug development and medicinal chemistry. Recent studies have explored its synthesis, biological activity, and potential therapeutic uses, making it a compound of interest for researchers aiming to develop novel pharmacological agents.

The compound's structure, featuring a nitro group and a propylamino substituent on a benzoate scaffold, suggests its potential as a precursor or intermediate in the synthesis of more complex molecules. Recent research has focused on optimizing its synthetic pathways to improve yield and purity, which are critical for its application in high-throughput screening and drug discovery programs. Advances in catalytic methods and green chemistry approaches have been particularly noteworthy in this context.

In terms of biological activity, methyl 3-nitro-4-(propylamino)benzoate has been investigated for its interactions with various enzymatic targets. Preliminary studies indicate that the nitro group may play a key role in its binding affinity, potentially making it a candidate for the development of enzyme inhibitors. Researchers have also explored its cytotoxicity and pharmacokinetic properties, with some studies suggesting moderate activity against specific cancer cell lines. However, further in vivo studies are needed to validate these findings and assess its therapeutic potential.

One of the most promising areas of research involves the derivatization of methyl 3-nitro-4-(propylamino)benzoate to enhance its pharmacological properties. Recent publications have reported the synthesis of novel analogs with improved solubility and bioavailability, addressing some of the limitations associated with the parent compound. These efforts are part of a broader trend in medicinal chemistry to optimize lead compounds for clinical development.

Despite these advances, challenges remain in fully elucidating the mechanism of action of methyl 3-nitro-4-(propylamino)benzoate and its derivatives. Computational modeling and structural biology techniques are being employed to gain deeper insights into its interactions at the molecular level. Collaborative efforts between academic and industrial researchers are expected to accelerate progress in this area, potentially leading to the identification of new drug candidates.

In conclusion, methyl 3-nitro-4-(propylamino)benzoate (CAS: 128429-03-8) represents a versatile scaffold with significant potential in drug discovery. Ongoing research aims to refine its synthesis, explore its biological activities, and develop derivatives with enhanced therapeutic profiles. As the field advances, this compound may serve as a valuable tool for understanding complex biological pathways and designing next-generation pharmaceuticals.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)